Gilead Sciences reinvests $11 billion to expand its manufacturing facilities in the United States.

Gilead Sciences, a biopharmaceutical company in the United States, announced that it will invest $11 billion in expanding pharmaceutical and research centers in the U.S. The company stated that this additional investment is on top of the previously announced $21 billion investment, and will mainly be used to build three new buildings and upgrade three existing factories, as well as introduce more advanced technology. The plan is expected to be completed by 2030. Gilead estimates that the $11 billion of new investment is expected to create at least 800 new jobs and 2,200 indirect jobs by 2028, bringing $43 billion in economic benefits to the United States. After President Trump proposed the possibility of imposing tariffs on imported drugs, many major pharmaceutical companies such as Gilead, Johnson & Johnson, and Merck have successively announced new investments in the United States.